Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Phase 1RecruitingNCT06989840

Sagimet Biosciences Inc.128 enrolled

Overview

This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be a randomized, open-label, 2-way crossover investigation to assess the effect of food on a single dose TVB-3567 administered orally in healthy participants. Parts C and D will be randomized, double-blind, placebo-controlled investigations of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants without and with moderate to severe acne, respectively.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

128

Conditions

Acne

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Healthy Participants (Parts A, B and C) 1. Healthy, adult, male or female 18-55 years of age 2. Body mass index (BMI) ≥18.0 and ≤32.0 kg/m2 3. Medically healthy with no clinically significant medical history 4. Understands the study procedures in the informed consent form (ICF) and willing and able to comply with the protocol Healthy Participants with Acne (Part D only) Participants must meet all of the above criteria, as well as the following inclusion criteria to be eligible for participation in the study: 1. BMI ≥18.0 and ≤37.0 kg/m2. 2. Must be diagnosed with moderate to severe acne vulgaris Exclusion Criteria: Healthy Participants (Parts A, B and C) 1. History or presence of clinically significant medical or psychiatric condition or disease 2. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds including over the counter acne products. 3. Has a clinically significant ophthalmic examination finding 4. Female participant of childbearing potential 5. Unable to refrain from or anticipates the use of: * Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements * Any topical anti-acne treatment on the face * Any drugs known to be moderate or strong inducers of CYP3A4 enzymes, BCRP, and/or P gp, including St. John's Wort, beginning 28 days prior to the first dosing. * Part C only: Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all-trans retinoic acid. Healthy Participants with Acne (Part D only) Participants must not be enrolled if they do not meet any of the above criteria, as well as the following exclusion criteria: 1. Unable to refrain from or anticipates the use of: * Any previous tretinoin treatments, including tazarotene, adapalene, isotretinoin, and all trans retinoic acid. * Photoelectric therapy, dermabrasion, or chemical peeling * Intra-articular and systemic corticosteroid therapy 2. Significant skin diseases

Locations (2)

Celerion, Inc.

Tempe, Arizona, United States

COMPLETED

Nucleus Network

Melbourne, Victoria, Australia

RECRUITING

Outcomes

Primary Outcomes

Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs)

Time frame: Baseline to 7 to 8 days after dosing

Part B - Plasma AUC0-t in fasted and fed conditions

Area under the concentration-time curve from time zero until the last observed concentration

Time frame: Baseline to Day 4

Part B - Plasma AUC0-inf in fasted and fed conditions

Area under the concentration-time curve from time zero to infinity

Time frame: Baseline to Day 4

Part B - Plasma Cmax in fasted and fed conditions

Maximum concentration measurement in plasma

Time frame: Baseline to Day 4

Part B - Incidence of adverse events (AEs) and serious adverse events (SAEs) under fasted and fed conditions

Time frame: Baseline to 7 to 8 days after dosing

Part C - Incidence of adverse events (AEs) and serious adverse events (SAEs)

Time frame: Baseline to 13 to 15 days after the last dose

Part D - Incidence of adverse events (AEs) and serious adverse events (SAEs)

Time frame: Baseline to 13 to 15 days after the last dose

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Central Contacts